Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)

NCT02373293 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2017-07-28

No results posted yet for this study

Summary

This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of moderate or severe acute pancreatitis.

Conditions

Sponsors & Collaborators

  • Alclinical Research, S.L.

    collaborator UNKNOWN
  • Francisco Javier García Borobia

    lead OTHER

Principal Investigators

  • Francisco Javier García Borobia, Dr. · Corporacion Parc Tauli

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-18
Primary Completion
2015-01-30
Completion
2017-08-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02373293 on ClinicalTrials.gov